Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs

Gain in-depth knowledge on oral selective estrogen receptor degrader (SERD) therapy and strategies for integrating SERDs for HR+/HER2- breast cancer cases in your clinical practice through an on-demand webcast, downloadable slides, and a podcast.

Share

Program Content

Activities

Evidence for SERDs Tx
The Expanding Evidence Base for Oral SERDs and Other ER-Targeting Agents
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 30, 2024

Expires: May 29, 2025

Future for SERDs Tx
Possibilities for the Future of SERDs Therapy for HR+/HER2- Breast Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 30, 2024

Expires: May 29, 2025

SERDs for ET Resistance
Steps Toward Precision Oncology: Role of SERDs in Attacking Endocrine Resistance in HR+/HER2- Breast Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 30, 2024

Expires: May 29, 2025

Activities

SERDs in Breast Cancer at ASCO 2024
Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs
Video
Congratulations: You achieved a completion on 04/09/2022

Released: June 18, 2024

Expires: June 17, 2025

Faculty

cover img faculity

Aditya Bardia, MD, MPH, FASCO

Professor of Medicine
Geffen School of Medicine at UCLA
Director, Breast Oncology Program
Assistant Chief (Translational Research)
Division of Medical Oncology
Director of Translational Research Integration
UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, California

cover img faculity

Virginia Kaklamani, MD, DSc

Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
A.B. Alexander Distinguished Chair in Oncology
Leader
Breast Oncology Program
UT Health San Antonio
MD Anderson Cancer Center
San Antonio, Texas

cover img faculity

Sarah Sammons, MD

Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca and Lilly.

AstraZeneca

Lilly